| Drug ID: | Drug76 |
|---|---|
| Drug Name: | Cannabidiol |
| CID: | 644019 |
| DrugBank ID: | DB09061 |
| Modality: | Small Molecule |
| Groups: | NULL |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT01562314, , NCT01037322, , NCT06353828 |
| Molecular Formula: | C21H30O2 |
| Molecular Weight: | 314.5 g/mol |
| Isomeric SMILES: | CCCCCC1=CC(=C(C(=C1)O)[C@@H]2C=C(CC[C@H]2C(=C)C)C)O |
| Synonyms: | cannabidiol; 13956-29-1; (-)-Cannabidiol; (-)-trans-Cannabidiol; CBD; (-)-CBD; GWP42003-P; CARDIOLRX; delta1(2)-trans-Cannabidiol; cannabidiolum |
| Phase 0: | 32 |
| Phase 1: | 122 |
| Phase 2: | 217 |
| Phase 3: | 92 |
| Phase 4: | 18 |
| Description: | NULL |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt645 | 644019 | Cannabidiol | 26 | AOC1 | Homo sapiens (human) | None | |
| dt646 | 644019 | Cannabidiol | 730755 | KRTAP2-3 | Homo sapiens (human) | 33244087 | Cannabidiol results in increased expression of KRTAP2-3 mRNA |
| dt647 | 644019 | Cannabidiol | 883 | KYAT1 | Homo sapiens (human) | 38663822 | Cannabidiol results in decreased expression of KYAT1 protein|cannabidiol results in decreased expression of KYAT1 mRNA |
| dt648 | 644019 | Cannabidiol | 79944 | L2HGDH | Mus musculus (house mouse) | 31052254 | Cannabidiol results in decreased expression of L2HGDH mRNA |
| dt649 | 644019 | Cannabidiol | 144811 | LACC1 | Danio rerio (zebrafish) | 33892503 | Cannabidiol affects the expression of LACC1 mRNA |
| dt650 | 644019 | Cannabidiol | 114294 | LACTB | Homo sapiens (human) | 27714895 | Cannabidiol results in increased expression of LACTB mRNA |
| dt651 | 644019 | Cannabidiol | 3898 | LAD1 | Danio rerio (zebrafish) | 33892503 | Cannabidiol affects the expression of LAD1 mRNA |
| dt652 | 644019 | Cannabidiol | 3903 | LAIR1 | Homo sapiens (human) | 36810933 | LAIR1 protein affects the reaction [cannabidiol results in decreased phosphorylation of MTOR protein]|cannabidiol results in increased expression of LAIR1 protein|lair1 protein affects the reaction [cannabidiol results in decreased phosphorylation of AKT1 |
| dt653 | 644019 | Cannabidiol | 284217 | LAMA1 | Homo sapiens (human) | 36519830 | Cannabidiol results in increased expression of LAMA1 mRNA |
| dt654 | 644019 | Cannabidiol | 3909 | LAMA3 | Danio rerio (zebrafish) | 33892503 | Cannabidiol affects the expression of LAMA3 mRNA |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| ACTRN12620000741987 | An Open Label, Multicenter, Observational Study to Assess the Safety, Tolerability and Efficacy of a Pharmaceutical grade Cannabis Medicine (MediCabilis CBD extract Oil) in Patients undergoing Medicinal Cannabis Therapy for Different Indications | Not Available | Not Recruiting | Bod Australia | Any approved condition for which MediCabilis has … | Assess safety, tolerability and efficacy of medic… | Details |
| NCT03467620 | Oral Cannabidiol Capsule Usage as an Adjunct Therapy for Crohn's Disease: a Randomized, Placebo-controlled Study | PHASE2|PHASE3 | Not recruiting | University of Illinois at Chicago | Crohn Disease;Inflammatory Bowel Diseases;Cannabis | Drug: Cannabidiol;Drug: Placebo oral capsule | Details |
| NCT01037322 | Cannabidiol for Inflammatory Bowel Disease | PHASE1|PHASE2 | COMPLETED | Meir Medical Center | Crohn's Disease|Ulcerative Colitis | DRUG: cannabidiol|DRUG: placebo in drops | Details |
| NCT06353828 | Phase 2a Study to Evaluate IcBD-01 Enema in Active Ulcerative Colitis Patients | PHASE2 | ACTIVE_NOT_RECRUITING | CannaMore Biotechs | Ulcerative Colitis | DRUG: CBD, synthetic form|DRUG: Placebo | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||
Differential Effects of D9 Tetrahydrocannabinol (THC)- and Cannabidiol (CBD)-Ba…
PMID: 35892693
Year: 2022
Relationship Type:
Treatment
Score: 9.5
Phytocannabinoids possess a wide range of immune regulatory properties, mediated by the endocannabinoid system. Monocyte/macrophage innate immune cel…
Inflammatory bowel disease patients believe cannabis and cannabidiol oil reliev…
PMID: 40687272
Year: 2025
Relationship Type:
Treatment
Score: 7.5
BACKGROUND: Patients with Inflammatory bowel disease (IBD) often seek alternative therapies for symptom management. This study investigates the perce…
Cannabidiol as an immune modulator: A comprehensive review
PMID: 40407987
Year: 2025
Relationship Type:
Treatment
Score: 7.5
Cannabidiol (CBD), a non-psychoactive phytocannabinoid derived from Cannabis sativa, has emerged as a promising therapeutic agent due to its diverse …
Enhancing Tetrahydrocannabinol's Therapeutic Efficacy in Inflammatory Bowel Dis…
PMID: 40005963
Year: 2025
Relationship Type:
Treatment
Score: 7.5
Background/Objectives: Current inflammatory bowel disease (IBD) treatments focus on symptomatic relief, highlighting the need for innovative approach…
Cannabidiol Targets Colorectal Cancer Cells via Cannabinoid Receptor 2, Indepen…
PMID: 39974647
Year: 2025
Relationship Type:
Treatment
Score: 7.5
Cannabidiol (CBD) is a non-neurotoxic, phytocannabinoid from cannabis with reported medicinal properties, including antiepileptic and anti-inflammato…
The Perceived Effectiveness of Cannabidiol on Adult Women with Inflammatory Bow…
PMID: 39768938
Year: 2024
Relationship Type:
Association
Score: 7.5
Background and Objectives: In this study we analyzed the perceived effectiveness of cannabidiol (CBD) in adult women with inflammatory bowel disease …
Comprehensive Assessment of Cannabidiol and HU308 in Acute and Chronic Colitis …
PMID: 39682761
Year: 2024
Relationship Type:
Treatment
Score: 7.5
Cannabinoids are emerging as promising treatments for inflammatory diseases such as ulcerative colitis. Specifically, cannabinoid 2 (CB2) receptors, …
The Modulatory Effects and Therapeutic Potential of Cannabidiol in the Gut
PMID: 39404382
Year: 2024
Relationship Type:
Treatment
Score: 7.5
Cannabidiol (CBD) is a major non-psychotropic phytocannabinoid that exists in the Cannabis sativa plant. CBD has been found to act on various recepto…
Dietary Cannabidiol Activates PKA/AMPK Signaling and Attenuates Chronic Inflamm…
PMID: 38175840
Year: 2024
Relationship Type:
Treatment
Score: 7.5
SCOPE: Inflammatory bowel disease (IBD) is characterized by chronic inflammation in the gut, accompanied by impaired epithelial integrity, increased …
Cannabidiol - Help and hype in targeting mucosal diseases
PMID: 37952828
Year: 2024
Relationship Type:
Treatment
Score: 7.5
Cannabidiol (CBD) is one of the most commonly utilised phytocannabinoids due to its non-psychoactive and multiple potential therapeutic properties an…
Cannabidiol and Intestinal Motility: a Systematic Review
PMID: 37786751
Year: 2023
Relationship Type:
Treatment
Score: 7.5
Cannabidiol (CBD) is a non-intoxicating cannabinoid extracted from the cannabis plant that is used for medicinal purposes. Ingestion of CBD is claime…
Cannabinoids as Immune System Modulators: Cannabidiol Potential Therapeutic App…
PMID: 36413346
Year: 2023
Relationship Type:
Treatment
Score: 7.5
Introduction: Cannabidiol (CBD) is the second most abundant Phytocannabinoid in Cannabis extracts. CBD has a binding affinity for several cannabinoid…
Fish Oil, Cannabidiol and the Gut Microbiota: An Investigation in a Murine Mode…
PMID: 33162890
Year: 2020
Relationship Type:
Treatment
Score: 7.5
Inflammatory bowel disorders can be associated with alterations in gut microbiota (dysbiosis) and behavioral disturbances. In experimental colitis, a…
Palmitoylethanolamide and Cannabidiol Prevent Inflammation-induced Hyperpermeab…
PMID: 31054246
Year: 2019
Relationship Type:
Mechanism
Score: 7.5
BACKGROUND AND AIMS: We aimed to examine, for the first time, the effect of cannabidiol (CBD) and palmitoylethanolamide (PEA) on the permeability of …
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Pilot Study of …
PMID: 29538683
Year: 2018
Relationship Type:
Treatment
Score: 7.3
BACKGROUND: Cannabidiol (CBD) exhibits anti-inflammatory properties that could improve disease activity in inflammatory bowel disease. This proof-of-…
Cannabidiol Limits T Cell-Mediated Chronic Autoimmune Myocarditis: Implications…
PMID: 26772776
Year: 2016
Relationship Type:
Treatment
Score: 7.3
Myocarditis is a major cause of heart failure and sudden cardiac death in young adults and adolescents. Many cases of myocarditis are associated with…
Cannabidiol reduces intestinal inflammation through the control of neuroimmune …
PMID: 22163000
Year: 2011
Relationship Type:
Treatment
Score: 7.1
Enteric glial cells (EGC) actively mediate acute and chronic inflammation in the gut; EGC proliferate and release neurotrophins, growth factors, and …
Cannabidiol and Other Non-Psychoactive Cannabinoids for Prevention and Treatmen…
PMID: 32357565
Year: 2020
Relationship Type:
Treatment
Score: 6.5
Cannabis sativa is an aromatic annual flowering plant with several botanical varieties, used for different purposes, like the production of fibers, t…
Oral CBD-rich Cannabis Induces Clinical but Not Endoscopic Response in Patients…
PMID: 33858011
Year: 2021
Relationship Type:
Treatment
Score: 5.5
AIMS: Despite reports that medical cannabis improves symptoms in Crohn's disease [CD], controlled studies evaluating disease response are lacking. Th…